Calls for papers
-
Adherium has announced that its Smartinhaler has been selected for use in the myAirCoach project, which will study the effectiveness of mHealth systems for asthma control. The program, which includes participation by Imperial College London,… Read more . . .
-
Following the signing of an international phase-down agreement regarding fluorinated gases in October 2016, pMDI propellent supplier Mexichem stated that it “does not believe the recent Kigali Amendment to the Montreal Protocol, nor regulatory controls… Read more . . .
-
H&T Presspart and Cohero Health have officially launched the eMDI connected metered dose inhaler (eMDI), which integrates with Cohero Health’s BreatheSmart inhaler tracking and lung function measurement platform. The two companies initially announced the eMDI… Read more . . .
-
OINDP development specialist Nanopharm has appointed Arron Danson as Head of Device Development, the company said. Danson has extensive experience in the development of pulmonary and nasal delivery devices, having worked at companies such as… Read more . . .
-
GlaxoSmithKline and Innoviva have announced that GSK has filed an MAA with the European Medicines Agency for its fluticasone furoate/umeclidinium/vilanterol DPI for the treatment of COPD. In November 2016, GSK submitted an NDA for the… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has received $21 million in the initial tranche of a Series C financing round, with another $15 million available on completion of development and business milestones, the company said. Investors… Read more . . .
-
GlaxoSmithKline and Innoviva have announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the 100/25 mcg strength of the Relvar Ellipta fluticasone furoate/vilanterol DPI for the treatment of COPD. Both the… Read more . . .
-
Aradigm Corporation has announced that top-line results from the Phase 3 ORBIT-3 and ORBIT-4 trials of Pulmaquin inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis bronchiectasis (non-CF BE)… Read more . . .
-
Intertek has announced the addition of morphologically-directed Raman spectroscopy (MDRS) capabilities to its OINDP analytical and development services with the acquisition of a Malvern Instruments Morphologi G3-ID. MDRS has the ability to distinguish API particle… Read more . . .
-
Avanir Pharmaceuticals, which launched its Onzetra Xsail intranasal dry powder sumatriptan in the US in May 2016, has announced the appointment of Richard Malamut as Senior VP, Research and Development and Chief Medical Officer. Malamut… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland